Search results

canagliflozin (Invokana®)

In adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as add-on therapy with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

canagliflozin plus metformin (Vokanamet)

In adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control

dapagliflozin + metformin (Xigduo)

in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients inadequately controlled on their maximally tolerated dose of metformin alone;in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products; n patients already being treated with the combination of dapagliflozin and metformin as separate tablets.

dapagliflozin (Forxiga)

For treatment of chronic heart failure

dapagliflozin (Forxiga)

Adults aged 18 and older with type 2 diabetes mellitus to improve glycaemic control as monotherapy/add-on combination therapy.

dapagliflozin (Forxiga)

In adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

dapagliflozin (Forxiga)

In adults for the treatment of chronic kidney disease (CKD).

dapagliflozin (Forxiga)

In adults for the treatment of insufficiently controlled T1DM as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

dapagliflozin (Forxiga)

For the treatment in adults of chronic kidney disease.

dapagliflozin (Forxiga)

For use in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

dapagliflozin (Forxiga)

In adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as add-on combination therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

saxagliptin/dapagliflozin fixed dose combination (Qtern)

in adults aged 18 years and older with type 2 diabetes mellitus: to improve glycaemic control when metformin and/or sulphonylurea and one of the monocomponents of Qtern® do not provide adequate glycaemic control. When already being treated with the free combination of dapagliflozin and saxagliptin

August 2023 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday, August 7) published advice on five medicines.

May 2022 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday May 9) published advice on eight new medicines.

September 2019 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 9 September) published advice accepting five new medicines.